For decades, liver cancer has stood as one of the deadliest malignancies worldwide, with a vast majority of cases intricately linked to chronic viral hepatitis infections. Despite its global impact, a significant challenge for researchers has been the absence of a reliable animal model that fully encapsulates the human progression from chronic viral hepatitis to liver cancer. This gap has hindered our detailed understanding of disease dynamics and the development of effective therapeutics. However, scientists at The Rockefeller University have now unveiled a groundbreaking mouse model that bridges this divide, offering unprecedented insight into the full spectrum of hepatitis-induced liver carcinogenesis.
Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) represents the dominant driver behind hepatocellular carcinoma (HCC), the predominant form of liver cancer and a leading cause of cancer-related mortality worldwide. Although the correlation between chronic viral hepatitis and HCC is well-established, the precise mechanisms by which these persistent infections evolve into malignant tumors remain elusive. This knowledge gap is partially attributable to the species-specific nature of hepatitis viruses, which has impaired the creation of animal models that faithfully mimic the disease timeline seen in humans.
Previous attempts to circumvent this obstacle have involved techniques such as viral adaptation, genetic humanization of murine liver cells, or transplantation of human liver tissues into mice. While these approaches have provided valuable insights, none have managed to replicate the natural course of chronic hepatitis advancing sequentially to scarring and ultimately liver cancer. The absence of an immunocompetent animal model that spontaneously develops HCC over time has limited preclinical evaluation of therapies and fundamental investigation into viral-host interactions during disease progression.
In a pioneering effort, researchers harnessed an engineered variant of Norway rat hepacivirus (NrHV), a viral relative of HCV known to infect the livers of wild rats in New York City, as a surrogate agent to establish persistent infection in standard laboratory mice. By transiently suppressing the mice’s immune systems at the onset, they allowed viral establishment before immune recovery. Over an 18-month observation period—analogous to middle age in humans—the team meticulously tracked disease progression, unveiling an impressive replication of human chronic hepatitis pathophysiology, culminating in spontaneous liver tumor formation.
The infected mice developed hallmark immune cell infiltrates and sustained liver inflammation mirroring human HCV-induced hepatitis. Fibrosis accumulated progressively over months, as evidenced by histological analyses, culminating in malignancy in a large majority of animals. Remarkably, by 18 months post inoculation, 67% of infected mice exhibited hepatocellular carcinoma, in stark contrast to merely 4% of control mice. Tumors bore striking histological resemblance to those found in human patients afflicted with HCV-related HCC, validating the model’s clinical relevance.
Moreover, the model captured sex-related disparities observed in human liver cancer. Male mice had more than twice the incidence of HCC compared to females, echoing epidemiological data demonstrating higher susceptibility among men. Intriguingly, a subset of mice that spontaneously cleared the virus still developed liver tumors, reflecting persistent oncogenic risk reported in hepatitis C patients even after viral eradication by direct-acting antivirals. This aspect offers a unique opportunity to explore residual carcinogenesis mechanisms beyond viral persistence.
This viral hepatitis mouse model transcends prior limitations by incorporating an intact immune system, enabling interrogation of complex immune-viral crosstalk during tumorigenesis. Understanding the relative contributions of viral oncogenic factors and immune-mediated inflammation to HCC development becomes feasible with this system. It provides a vital platform to dissect immune evasion strategies, chronic inflammation’s role, and microenvironmental changes facilitating malignant transformation.
Clinically, the model paves the way to rigorously evaluate existing and novel immune-based therapies for liver cancer within a relevant physiological context. Investigators can now investigate why therapies such as immune checkpoint inhibitors display variable efficacy among patients. Moreover, it offers a testing ground for emerging antiviral and anticancer treatments, optimizing therapeutic regimens prior to clinical translation. Early-stage biomarker discovery efforts aimed at identifying indicators predictive of HCC onset also stand to benefit, potentially enabling earlier diagnosis and intervention in human patients.
The innovative work spearheaded by Charles M. Rice and Mariana Nogueira Batista at The Rockefeller University epitomizes scientific advancement by effectively reproducing the complex natural history of hepatitis progressing to liver cancer in an accessible and reproducible animal model. This leap forward will undoubtedly accelerate research into viral hepatitis, liver fibrosis, and hepatocellular carcinoma, ultimately aiding the development of targeted therapies to alleviate a major global health burden. As the model continues to be employed for mechanistic studies and preclinical trials, hope grows for improved patient outcomes through enhanced understanding and novel treatment possibilities.
This new animal model stands as a testament to the power of combining virology, immunology, and cancer biology to solve longstanding challenges. By faithfully mimicking the human disease continuum, it opens unforeseen avenues for scientific inquiry and therapeutic innovation, moving us closer to conquering one of the deadliest cancers worldwide.
Subject of Research: Development of a chronic viral hepatitis mouse model that progresses to hepatocellular carcinoma analogous to hepatitis C virus infection in humans.
Article Title: (Not explicitly stated in content)
News Publication Date: (Not provided)
Web References:
http://dx.doi.org/10.1016/j.jhep.2026.02.020
References: Journal of Hepatology
Image Credits: Laboratory of Virology and Infectious Disease at The Rockefeller University
Keywords: Hepatitis C, Liver cancer, Hepatocellular carcinoma, Viral hepatitis, Norway rat hepacivirus, Chronic infection, Immune system, Liver fibrosis, Animal model, Immunology, Cancer biology, Preclinical trials.
